Fig. 6.

Immune humanization of mice bearing HCI-013EI PDX tumors. a Experimental timeline. 6–7 weeks old NSG-SGM3 female mice were injected with 20 mg/kg/day busulfan on two consecutive days. Five days later, mice were IV injected with 85,000 hCD34⁺ HSCs and 24 h later implanted with HCI-013EI tumor fragments into the MFP, without exogenous E2 supplementation. Animals were harvested 12 weeks post-humanization (n = 10, HSC donor ID 7734, KIR-mismatched to HCI-013). b Flow cytometry of hCD45⁺ cells in BM, blood and spleen of humanized mice are shown as percent of viable cells (n = 9). c Flow cytometry of hCD11b⁺, hCD3⁺, hCD56⁺ and hCD19⁺ cells in BM, blood and spleens of humanized mice are shown as percent of hCD45⁺ cells (n = 9). d HCI-013EI tumor growth of humanized mice compared to non-humanized control mice (humanized n = 9, controls, n = 5). e Representative images of double IHC stains of HCI-013EI PDX tumors from humanized and control mice. Upper panel: CAM5.2 (red) and PHH3 (blue). Lower panel: CAM5.2 (red) and CC3 (blue). f Quantification of e showing PHH3+ or CC3+ cells as percentages of total cells detected in HCI-013EI PDX tumors across both groups. g Quantification of e showing CAM5.2+ and CAM5.2− cells as percentages of all proliferating PHH3+ cells detected in HCI-013EI PDX tumors across both groups. All data shown as mean ± SEM